Company Performance Metrics
Douglas J. Duchon: Vice President of Research & DevelopmentPast Role: Worrell Design, Managed Design Consultancy Engineering Group
Pamela G. Unger: Vice President of Clinical Research & ReimbursementPast Role: American Physical Therapy Association(APTA), President of Section on Clinical ElectroPhysiology & Wound Management
Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform.
Celleration’s core product, the MIST Ultrasound Healing Therapy® System delivers low frequency ultrasound through a saline mist. Unlike conventional wound treatments that are limited to treating the
surface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells to positively impact all critical aspects of the wound healing process.
Celleration received 510K clearance from the FDA in 2005 with the full claim of “promote wound healing”. Shortly thereafter, the company introduced the MIST Therapy System to the US market and has since built an impressive body of clinical evidence demonstrating significant clinical and economic benefits in hundreds of facilities across the United States. Currently, over over 1 million MIST® Therapy treatments have been performed in the United States and U.K. benefiting more than 65,000 patients.
